• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement

    Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement

  2. Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says

    Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says

  3. Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

    Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

  4. U.S. FDA Approves Biogen ’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy

    U.S. FDA Approves Biogen ’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy

  5. U.S. FDA Approves Biogen ’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy

    U.S. FDA Approves Biogen ’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy

  6. Biotech Boom, or Bubble?

    All investments involve risk, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. The information provided in this posting is not a complete analysis of every material fact regarding any country, region, ...

  7. Betting Responsibly on Healthcare

    These funds offer thoughtful investments in healthcare, not tactical plays.

  8. 10 High-Conviction Purchases by Our Ultimate Stock-Pickers

    Our top managers continue to find attractive buying opportunities in wide-moat firms.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.